1-(3-溴苯基)环丙烷羧酸 | 124276-95-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-溴苯基)环丙烷羧酸
• 中文别名: 1-(3-溴苯基)环丙烷甲酸
• 英文名称: 1-(3-bromophenyl)cyclopropane-1-carboxylic acid
• 英文别名: 1-(3-bromophenyl)cyclopropanecarboxylic acid
• CAS: 124276-95-5
• 化学式: C₁₀H₉BrO₂
• mdl: MFCD07374441
• 分子量: 241.084
• InChiKey: MYDCJGVBYNDHIC-UHFFFAOYSA-N

物化性质

• 沸点：
  367.6±35.0 °C(Predicted)
• 密度：
  1.67

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(3-Bromophenyl)cyclopropanecarboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(3-Bromophenyl)cyclopropanecarboxylic acid
CAS number: 124276-95-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H9BrO2
Molecular weight: 241.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-溴苯基)环丙烷羧酸 在 sulfur tetrafluoride 、 氢氟酸 作用下， 以 二氯甲烷 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  [EN] A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES
  [FR] NOUVEAU PROCÉDÉ DE SYNTHÈSE DE 1-ARYL-1-TRIFLUOROMÉTHYLCYCLOPROPANES

  摘要：

  本发明涉及一种用于制造1-芳基-1-三氟甲基环丙烷的工艺，该环丙烷作为通用式(A)中描述的钙T通道阻滞剂的制造中间体，该通用式已在WO 2015/186056中描述。

  公开号：

  WO2018141961A1
• 作为产物：
  描述：

  3-溴氰苄 在 苄基三乙基氯化铵 、 sodium hydroxide 、 lithium hydroxide 作用下， 以 水 、 乙二醇 为溶剂， 反应 36.0h， 生成 1-(3-溴苯基)环丙烷羧酸
  参考文献：
  名称：

  手性双齿硼酸配体使环丙烷的铱催化对映选择性 C(sp3)-H 硼酸化成为可能

  摘要：

  我们在此报告了首次使用手性双齿硼酸配体对环丙烷甲酰胺进行 Ir 催化的对映选择性 C(sp3)-H 硼酸化。具有 α-季碳中心的多种底物可以在该反应中相容，以提供具有良好至优异对映选择性的 β-硼酸化产物。我们还证明，硼酸化产物可用作多功能前体，参与 CB 键的立体有择转化，包括合成生物活性化合物 Levomilnacipran。

  DOI：

  10.1021/jacs.9b04549

文献信息

• [EN] LXR MODULATORS<br/>[FR] MODULATEURS DE LXR
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014152738A1

  公开（公告）日：2014-09-25

  The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs.

  本发明提供了Formula I和Formula II的化合物：或其药学上可接受的盐或溶剂，作为肝X受体（LXRs）的调节剂，以及包含任何此类新化合物的组合物和使用方法。这些化合物可用作治疗和/或预防与LXRs活性相关的疾病或病况的药物。
• [EN] SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLYLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE CDK
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2016193939A1

  公开（公告）日：2016-12-08

  The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

  本发明提供了公式（I）的取代杂环基衍生物，其在治疗上具有用途，特别是作为选择性转录CDK抑制剂，包括CDK7、CDK9、CDK12、CDK13和CDK18，更具体地是转录CDK7抑制剂。这些化合物在治疗和预防与哺乳动物中选择性转录CDK相关的疾病和/或疾病方面具有用途。本发明还提供了这些化合物的制备以及包含至少一种公式（I）的取代杂环基衍生物或其药学上可接受的盐或立体异构体的制药配方。
• 螺环2,3-二氢-7-氮杂吲哚化合物及其用途
  申请人：豪夫迈·罗氏有限公司

  公开号：CN113015526A

  公开（公告）日：2021-06-22

  本发明提供式(I)的螺环2,3‑二氢‑7‑氮杂吲哚化合物：所述式的变体的所述化合物，以及所述化合物作为HPK1(造血激酶1)抑制剂的用途。所述化合物可用于治疗HPK1依赖性疾患以及增强免疫应答。本公开还描述了抑制HPK1的方法、治疗HPK1依赖性疾患的方法、用于增强免疫应答的方法以及用于制备所述螺环2,3‑二氢‑7‑氮杂吲哚化合物的方法。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CATHEPSINE ET DE CYSTEINE PROTEASE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005019161A1

  公开（公告）日：2005-03-03

  This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一类新颖的化合物，其由下述公式表示，其中G、E、E、n、R1、R2、R3和R4的含义如公式中所示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于组织蛋白酶K、L、S和B的抑制剂。这些化合物可用于治疗那些指示抑制骨吸收的疾病，例如骨质疏松症。
• Systematic Investigation of Halogen Bonding in Protein–Ligand Interactions
  作者：Leo A. Hardegger、Bernd Kuhn、Beat Spinnler、Lilli Anselm、Robert Ecabert、Martine Stihle、Bernard Gsell、Ralf Thoma、Joachim Diez、Jörg Benz、Jean‐Marc Plancher、Guido Hartmann、David W. Banner、Wolfgang Haap、François Diederich

  DOI：10.1002/anie.201006781

  日期：2011.1.3

  Halogen bonding triggers activity: Increasing binding affinity was observed for a series of covalent human Cathepsin L inhibitors by exchanging an aryl ring H atom with Cl, Br, and I, which undergo halogen bonding with the CO group of Gly61 in the S3 pocket of the enzyme. Fluorine, in contrast, strongly avoids halogen bonding (see scheme). The strong distance and angle dependence of halogen bonding

  卤素键触发活性：通过将芳环H原子与Cl，Br和I交换，可以观察到一系列共价的人组织蛋白酶L抑制剂的结合亲和力增加，Cl，Br和I与S3口袋中的Gly61的CO基团进行卤素键合酶。相反，氟强烈避免卤素键（参见方案）。卤素键的强距离和角度依赖性已被证实适用于生物系统。